<scp>VI‐RADS</scp> for Bladder Cancer: Current Applications and Future Developments
-
- Valeria Panebianco
- Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
-
- Martina Pecoraro
- Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
-
- Francesco Del Giudice
- Department of Maternal‐Infant and Urological Sciences Sapienza/Policlinico Umberto I Rome Italy
-
- Mitsuru Takeuchi
- Department of Radiology Radiolonet Tokai Nagoya Japan
-
- Valdair F. Muglia
- Department of Medical Images, Radiation Therapy and Oncohematology, Ribeirao Preto Medical School University of Sao Paulo Ribeirao Preto Brazil
-
- Emanuele Messina
- Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
-
- Stefano Cipollari
- Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
-
- Gianluca Giannarini
- Urology Unit Academic Medical Centre “Santa Maria della Misericordia” Udine Italy
-
- Carlo Catalano
- Department of Radiological Sciences, Oncology and Pathology Sapienza/Policlinico Umberto I Rome Italy
-
- Yoshifumi Narumi
- Department of Healthcare Tachibana University Kyoto Japan
説明
<jats:sec><jats:label /><jats:p>Bladder cancer (BCa) is among the ten most frequent cancers globally. It is the tumor with the highest lifetime treatment‐associated costs, and among the tumors with the heaviest impacts on postoperative quality of life. The purpose of this article is to review the current applications and future perspectives of the Vesical Imaging Reporting and Data System (VI‐RADS). VI‐RADS is a newly developed scoring system aimed at standardization of MRI acquisition, interpretation, and reporting for BCa. An insight will be given on the BCa natural history, current MRI applications for local BCa staging with assessment of muscle invasiveness, and clinical implications of the score for disease management. Future applications include risk stratification of nonmuscle invasive BCa, surveillance, and prediction and monitoring of therapy response.</jats:p></jats:sec><jats:sec><jats:title>Level of Evidence</jats:title><jats:p>3</jats:p></jats:sec><jats:sec><jats:title>Technical Efficacy Stage</jats:title><jats:p>2</jats:p></jats:sec>
収録刊行物
-
- Journal of Magnetic Resonance Imaging
-
Journal of Magnetic Resonance Imaging 55 (1), 23-36, 2020-09-17
Wiley